Quarterly ResultMay 6, 2026, 04:13 PM

RxSight Q1 Sales Down 18.5% to $30.9M; Net Loss Widens to $15.9M

AI Summary

RxSight reported a significant decline in sales for Q1 2026, with revenue falling 18.5% to $30.9 million compared to the prior year. The company's net loss widened to $15.9 million, or $(0.38) per share, from a net loss of $8.2 million, or $(0.20) per share, in Q1 2025. Operating expenses increased, contributing to the larger loss. Despite the losses, RxSight believes its existing cash resources of $217.9 million are sufficient for at least the next 12 months.

Key Highlights

Q1 2026 Sales: $30.9 million, down 18.5% from $37.9 million in Q1 2025.
Q1 2026 Net Loss: $(15.9) million, compared to $(8.2) million in Q1 2025.
Q1 2026 Basic & Diluted Net Loss per share: $(0.38), up from $(0.20) in Q1 2025.
Gross profit for Q1 2026: $23.5 million, down from $28.3 million in Q1 2025.
Operating expenses for Q1 2026: $41.3 million, up from $39.0 million in Q1 2025.
Cash, cash equivalents, and short-term investments: $217.9 million as of March 31, 2026.
Net cash used in operating activities: $(10.9) million in Q1 2026.

View SEC Filing

RXST

Ophthalmic Goods

RxSight, Inc.

Price Impact